Subsequently, a novel prognostic signature, termed MIRGs, was constructed, comprising 13 genes: CD36, VCAN, SERPINE1, SLC24A2, RAG2, APOH, LGR6, CER1, VTN, NPR3, GRP, RNASE3, and EGF. MIRGs effectively categorized GC patients into high-risk and low-risk groups, with the high-risk group demonstrating reduced overall survival time and poorer survival rates. This evidence concerns the gene VTN and gastric cancer.